Bioxytran, INC Form 4 insider transactions

OQB

27 Mar 2024

BIXT

Form 4: Bioxytran CEO David Platt Reports Acquisition of Common Stock

David Platt, CEO of Bioxytran, Inc., reports the acquisition of 439,595 shares of common stock at $0.104 per share, along with indirect ownership through NDPD Pharma, Inc.

OQB

27 Mar 2024

BIXT

Bioxytran, INC

Form 4: Bioxytran Director Alan Hoberman Reports Acquisition and Disposal of Common Stock

Director Alan Hoberman reports acquiring and disposing of Bioxytran, Inc. (BIXT) common stock on March 27, 2024.